CVR 41124369Private limited company (ApS)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)København ØFounded 23 Jan 2020
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about p.A.c. ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
1
CVR, 2023
Gross profit
-354K
DKK, annual report 2025
Result
-2.5M
DKK, annual report 2025
Equity
-24.4M
DKK, annual report 2025
MOLIOR HOLDING ApSCVR 35257918, 33.3% to under 50% of capital and votes, until 9 Jul 2026
Hadrup BioMed Holding ApSCVR 38034871, 33.3% to under 50% of capital and votes, until 9 Jul 2026
and 1 moreAnne Reker Cordtuntil 19 Jul 2023
Sine Hadrupuntil 19 Jul 2023
No current owner is registered.
CVR 3525791833.3% to under 50% of capital and votes23 Jan 2020 to 9 Jul 2026
CVR 3803487133.3% to under 50% of capital and votes23 Jan 2020 to 9 Jul 2026
CVR 4103389433.3% to under 50% of capital and votes23 Jan 2020 to 9 Jul 2026
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR lists no current officers for this company.
Founded 23 Jan 2020.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Oct 2023, monthly: 1 employee, 0 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 5 | 6 | 9 | 10 | 10 | 9 | 9 | 9 | 8 | 9 | 9 | 9 | 8 | 8 | 8 | 10 | 10 | 7 | 7 | 7 | 6 | 5 | 5 | 5 | 5 | 5 | 6 | 5 | 4 | 4 | 3 | 1 |
| FTE | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 4 | 6 | 8 | 9 | 9 | 8 | 8 | 8 | 7 | 8 | 8 | 8 | 7 | 7 | 7 | 9 | 9 | 7 | 7 | 7 | 6 | 5 | 5 | 4 | 4 | 5 | 4 | 3 | 3 | 3 | 2 | 0 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Oct 2023, published 20 Dec 2023.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2025, DKK: Gross profit -354K, Operating profit -354K, Result for the year -2.5M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 6.4M, Equity -24.4M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | -3,393 | -4,546 | 1,545 | -717 | -354 |
| Operating profit | Not reported | Not reported | -3,821 | -2,169 | -354 |
| Result for the year | -4,855 | -9,184 | -4,396 | -3,503 | -2,545 |
| Equity | -4,815 | -13,999 | -18,395 | -21,898 | -24,443 |
| Total assets | 15,786 | 10,624 | 7,643 | 6,817 | 6,391 |
| Employees (average) | 3 | Not reported | 6 | 2 | 0 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | Not reportednote 1 | n.m.note 2 | n.m.note 2 | -146.5% | n.m.note 2 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Employee growth (vækst i antal ansatte) | Not reportednote 1 | Not reportednote 3 | -25% | -66.7% | -100% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Not every period is a full year: 2021 covers 14 months (23 Jan 2020 to 31 Mar 2021). Changes against it compare periods of different length.
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
Annual report 2025
1 Apr 2024 to 31 Mar 2025, published 29 Sep 2025
Annual report 2024
1 Apr 2023 to 31 Mar 2024, published 14 Oct 2024
Annual report 2023
1 Apr 2022 to 31 Mar 2023, published 3 Oct 2023
Annual report 2022
1 Apr 2021 to 31 Mar 2022, published 3 Oct 2022
Annual report 2021
23 Jan 2020 to 31 Mar 2021, published 31 Aug 2021
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for p.A.c. ApS:
Have Pro? Sign in.
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| FoundingCashPaid in 40,000 | None | 40,000 | None | 40,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Source: CVR, read 19 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
6 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Likvidation sluttet, og virksomheden opløst
Likvidatorer:
Fratrådte:
Nicholas Lerche-Gredal, den 09.07.2026.
Ny adresse: c/o DLA Piper Denmark, Oslo Plads 2, 2100 København Ø
Likvidation vedtaget 19.07.2023
Likvidatorer:
Tiltrådte:
Advokat Nicholas Lerche-Gredal, 2100 København Ø, den 19.07.2023.
Bestyrelse:
Fratrådte:
Anne Reker Cordt, den 19.07.2023, Sine Hadrup, (formand), den 19.07.2023, Søren Nyboe Jakobsen, den 19.07.2023.
Direktion:
Fratrådte:
Anne Reker Cordt, den 19.07.2023, Sine Hadrup, den 19.07.2023.
Virksomheden tegnes af en likvidator
Virksomhedens kreditorer opfordres til at anmelde deres krav til likvidator. Krav skal anmeldes senest tre måneder fra dags dato.
Vedtægter ændret: 19.07.2023
Nyt navn: p.A.c. ApS
Vedtægter ændret: 18.11.2020
Ny adresse: c/o BioInnovation Institute, Ole Maaløes Vej 3, 3., 2200 København N
Ny kommune: København
Stiftelsesdato: 23.01.2020.
Virkningsdato: 23.01.2020.
Seneste vedtægtsdato: 23.01.2020.
Kapital:
kr. 40.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 40.000,00 til kurs 100,00, fuldt indbetalt.
Stiftere:
CVR-NR. 35257918 MOLIOR HOLDING ApS, c/o Søren Jakobsen, Vintervej 6, 1., 2920 Charlottenlund, den 23.01.2020, CVR-NR. 38034871 Hadrup BioMed Holding IVS, Kirkebakken 12, 2830 Virum, den 23.01.2020, CVR-NR. 41033894 BIOARC HOLDING APS, Storkevænget 6, 2840 Holte, den 23.01.2020.
Bestyrelse:
Sine Hadrup, (formand), den 23.01.2020, Anne Reker Cordt, den 23.01.2020, Søren Nyboe Jakobsen, den 23.01.2020.
Direktion:
Anne Reker Cordt, den 23.01.2020, Sine Hadrup, den 23.01.2020.
Selskabet tegnes af en direktør eller bestyrelsesformanden..
Første regnskabsår:
23.01.2020 - 31.03.2021.
Regnskabsår:
01.04 - 31.03.
Formål:
Selskabets formål er at bedrive forskning, udvikling, licensering og salg af terapeutiske produkter og teknologi til brug inden for naturvidenskabelig forskning, patientbehandling og relaterede forretningsområder.
P-number 1025506320Oslo Plads 2, 2100 København Ø